Literature DB >> 1905989

Pulmonary effects of continuous endotoxin infusion in the rat.

R K Simons1, R V Maier, E Y Chi.   

Abstract

A major hindrance to the elucidation of the pathogenesis of the adult respiratory distress syndrome (ARDS) is the lack of an animal model consistent with the clinical course in humans. A continuous intravenous infusion of endotoxin (LPS) over a several day period was used to more closely parallel the clinical setting. Male Sprague-Dawley rats infused with LPS via indwelling right atrial catheters become tachypneic, lethargic and anorectic with a steady loss in body weight. Serial blood gas analyses demonstrate an early respiratory alkalosis followed by increasing acidosis and hypoxia. Lungs demonstrate 1) pulmonary leukoaggregation, 2) interstitial and intraalveolar edema, 3) Type I pneumocyte injury, 4) proliferation of Type II pneumocytes, and 5) thickening of the microvascular walls. Differential neutrophil count in bronchoalveolar lavage (BAL) fluid increased from 1% to a peak of 59.1% +/- 3.0% and protein content was elevated. A prolonged infusion of LPS in the rat produces a lung injury which mimics many of the pathophysiologic and histologic features associated with sepsis-induced ARDS in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905989

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  10 in total

1.  One-hit, two-hit . . . is there really any benefit?

Authors:  J D Lang; J M Hickman-Davis
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

2.  Ameliorating effects of low tidal volume ventilation with associated hypercapnia on pneumoperitoneum-induced lung injury by inhibition of Toll-like receptor 4.

Authors:  Shenqiang Gao; Shanhui Guan; Hongyan Li; Aiping Su; Yuelan Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Lipopolysaccharide induced apoptosis of rat pancreatic acinar cells.

Authors:  V J Laine; K M Nyman; H J Peuravuori; K Henriksen; M Parvinen; T J Nevalainen
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

4.  Characteristics of neutrophil influx in rat lungs following fecal peritonitis.

Authors:  J G Peralta; M L Barnard; J F Turrens
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

5.  Inhibition of HA synthase 3 mRNA expression, with a phosphodiesterase 3 inhibitor, blocks lung injury in a septic ventilated rat model.

Authors:  Hicham Mrabat; John Beagle; Zhao Hang; Hari G Garg; Charles A Hales; Deborah A Quinn
Journal:  Lung       Date:  2009-07-02       Impact factor: 2.584

6.  Naringenin ameliorates LPS-induced acute lung injury through its anti-oxidative and anti-inflammatory activity and by inhibition of the PI3K/AKT pathway.

Authors:  Minghong Zhao; Chao Li; Fujun Shen; Meijuan Wang; Ning Jia; Chunbin Wang
Journal:  Exp Ther Med       Date:  2017-07-11       Impact factor: 2.447

7.  Evolution of endotoxin induced acute lung injury in the rat.

Authors:  L Domenici-Lombardo; C Adembri; M Consalvo; R Forzini; M Meucci; P Romagnoli; G P Novelli
Journal:  Int J Exp Pathol       Date:  1995-10       Impact factor: 1.925

8.  Respiratory gas exchange as a new aid to monitor acidosis in endotoxemic rats: relationship to metabolic fuel substrates and thermometabolic responses.

Authors:  Alexandre A Steiner; Elizabeth A Flatow; Camila F Brito; Monique T Fonseca; Evilin N Komegae
Journal:  Physiol Rep       Date:  2017-01

9.  Targeting myeloid differentiation protein 2 by the new chalcone L2H21 protects LPS-induced acute lung injury.

Authors:  Yali Zhang; Tingting Xu; Beibei Wu; Hongjin Chen; Zheer Pan; Yi Huang; Liqin Mei; Yuanrong Dai; Xing Liu; Xiaoou Shan; Guang Liang
Journal:  J Cell Mol Med       Date:  2016-11-18       Impact factor: 5.310

10.  Idh2 Deficiency Exacerbates Acrolein-Induced Lung Injury through Mitochondrial Redox Environment Deterioration.

Authors:  Jung Hyun Park; Hyeong Jun Ku; Jin Hyup Lee; Jeen-Woo Park
Journal:  Oxid Med Cell Longev       Date:  2017-12-31       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.